Flash glucose monitoring system: impact on glycemic control and body mass index in type 1 diabetes mellitus

OBJECTIVE: Flash glucose monitoring (FGM) is increasingly used in type 1 diabetes mellitus (T1D) management. This study aimed to assess glycated hemoglobin (HbA1c) and body mass index (BMI) in the first year of FGM use in patients with T1D and to identify predictive factors of benefit associated with its use. SUBJECTS AND METHODS: Retrospective study of T1D patients, using FGM for ≥ 6 months and under intensive insulin therapy with multiple daily injections. RESULTS: In 179 patients with a median (Md) age of 43.0 years (P25 31.0; P75 52.0) and disease duration of 18.0 years (P25 10.0; P75 28.0), initial HbA(1)c was 7.9% (P25 7.2; P75 8.8) and initial BMI was 24.0 kg/m(2) (P25 21.9; P75 26.2). With FGM, HbA1c improved significantly to 7.6% (P25 7.0; P75 8.3) at 6 months and 7.7% (P25 6.95; P75 8.5) at 12 months (p < 0.05), with more patients with HbA(1)c < 7% (16.1% vs 22.5%) and fewer patients with HbA(1)c ≥ 8% (49.1% vs 35.8%) (p < 0.05). Initial HbA(1)c 8.0-8.9% (HR 1.886; 95% CI 1.321-2.450) and ≥ 9.0% (HR 3.108, 95% CI 2.454-3.761) predicted greater HbA(1)c reduction. BMI increased significantly, especially between 6 and 12 months (BMI Md 23.8 [P25 21.9; P75 26.2] kg/m(2) and 24.0 [P25 22.0; P75 26.2] kg/m(2), respectively) (p < 0.05). Overweight (HR 4.319, 95% CI 3.185-5.453) and obesity (HR 8.112, 95% CI 3.919-12.306) predicted greater weight gain. CONCLUSIONS: FGM use was associated with significant improvement in HbA(1)c, mainly in patients with worse previous glycemic control. It was also associated with increased BMI, especially if baseline BMI ≥ 25 kg/m(2), so weight control strategies should be emphasized.